Back to Search
AMIT RAKHIT, M.D.
M.D.
Pediatric Cardiology Physician
NPI: 1730480336Individual
Specialties, Licenses & Credentials
Pediatrics Physician
Pediatrics
Code: 208000000X
224179-1(NY)
Pediatric Cardiology PhysicianPrimary
Pediatrics — Pediatric Cardiology
Code: 2080P0202X
224179-1(NY)
Research & Publications (17)
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.
PMID 18249110·Eur J Cancer·2008
3-trial
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals.
PMID 18176118·Anticancer Drugs·2008
2-rct
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
PMID 18000659·Eur J Clin Pharmacol·2008
2-rct
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
PMID 17986625·Ann Oncol·2008
3-trial
Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference?
PMID 17592082·Circulation·2007
4-observational
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
PMID 17255274·Clin Cancer Res·2007
3-trial
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
PMID 16890575·Clin Pharmacol Ther·2006
3-trial
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
PMID 16490804·J Clin Pharmacol·2006
3-trial
Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.
PMID 16381666·Drug Metab Dispos·2006
8-other
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
PMID 16144928·Clin Cancer Res·2005
3-trial
Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.
PMID 12419754·Ann Oncol·2002
3-trial
Gastrointestinal complications after pediatric cardiac transplantation.
PMID 12100901·J Heart Lung Transplant·2002
8-other
In vivo electrophysiologic studies in endothelial nitric oxide synthase (eNOS)-deficient mice.
PMID 11761419·J Cardiovasc Electrophysiol·2001
4-observational
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
PMID 11359657·J Interferon Cytokine Res·2001
3-trial
Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
PMID 11230473·J Clin Oncol·2001
3-trial
A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B.
PMID 10707873·J Hepatol·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 181 7TH AVE, SUITE 9B
NEW YORK, NY 10011 - Phone
- (917) 859-0545
Quick Facts
- NPI
- 1730480336
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 17
Are you this provider?
Claim Your Profile